IDEXX Laboratories (IDXX)
Healthcare
Close on Nov 12, 2026 (from our latest Long View update): $698.02
- Market value
- $55.0Bat the Nov 12 close
- Revenue growth
- +12%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- 28%12 months to Sep 30, 2026 (10-Q)
- Net debt
- $651Mat Sep 30, 2026
- Worst fall since listing
- −81.4%Feb 5, 1996 to Apr 18, 1997; back to that high in Mar 2004
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
IDEXX grew revenue every year from 2021 to 2025, from $3.22B to $4.30B, and spent about as much on buybacks as it generated in free cash flow (operating cash flow minus capital spending; our calculation), while its share price swung widely.
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 12, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for IDEXX Laboratories, FY2009–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $1.0B in FY2009 to $4.3B in FY2025.
Free cash flow was positive in 17 of the 17 years shown; FY2025: $1.1B.
Margins
Operating margin was 32% in FY2025, vs 26% in FY2020.
Gross margin was 62% in FY2025, vs 58% in FY2020.
Diluted share count
The diluted share count fell 7% from FY2020 to FY2025, to 81M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $4.3B | 62% | 32% | $1.1B | $1.2B | $125M | $1.1B |
| FY2024 | $3.9B | 61% | 29% | $888M | $929M | $121M | $808M |
| FY2023 | $3.7B | 60% | 30% | $845M | $907M | $134M | $773M |
| FY2022 | $3.4B | 60% | 27% | $679M | $543M | $149M | $394M |
| FY2021 | $3.2B | 59% | 29% | $745M | $756M | $120M | $636M |
| FY2020 | $2.7B | 58% | 26% | $582M | $648M | $107M | $541M |
| FY2019 | $2.4B | 57% | 23% | $428M | $459M | $155M | $304M |
| FY2018 | $2.2B | 56% | 22% | $377M | $400M | $116M | $284M |
| FY2017 | $2.0B | 56% | 21% | $263M | $373M | $74M | $299M |
| FY2016 | $1.8B | 55% | 20% | $222M | $339M | $65M | $274M |
| FY2015 | $1.6B | 56% | 19% | $192M | $222M | $83M | $139M |
| FY2014 | $1.5B | 55% | 18% | $182M | $236M | $61M | $175M |
| FY2013 | $1.4B | 55% | 19% | $188M | $246M | $78M | $168M |
| FY2012 | $1.3B | 54% | 20% | $178M | $222M | $58M | $165M |
| FY2011 | $1.2B | 53% | 19% | $162M | $218M | $50M | $168M |
| FY2010 | $1.1B | 52% | 18% | $141M | $179M | $39M | $140M |
| FY2009 | $1.0B | 51% | 17% | $122M | $175M | $51M | $124M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 81M | $180M | $848M | $60M | — | $1.2B |
| FY2024 | 83M | $288M | $868M | $60M | — | $837M |
| FY2023 | 84M | $454M | $948M | $60M | — | $72M |
| FY2022 | 85M | $113M | $1.3B | $50M | — | $820M |
| FY2021 | 87M | $144M | $851M | $38M | — | $747M |
| FY2020 | 87M | $384M | $909M | $31M | — | $183M |
| FY2019 | 88M | $90M | $988M | $39M | — | $302M |
| FY2018 | 88M | $124M | $1.0B | $25M | — | $369M |
| FY2017 | 90M | $472M | $1.3B | $24M | — | $283M |
| FY2016 | 91M | $392M | $1.2B | $20M | — | $304M |
| FY2015 | 94M | $343M | $1.2B | $20M | — | $402M |
| FY2014 | 102M | $323M | $899M | $18M | — | $618M |
| FY2013 | 108M | $279M | $428M | $17M | — | $368M |
| FY2012 | 112M | $224M | $215M | $16M | — | $132M |
| FY2011 | 116M | $184M | $246M | $15M | — | $256M |
| FY2010 | 119M | $157M | $132M | $13M | — | $143M |
| FY2009 | 121M | $107M | $123M | $12M | — | $83M |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 12, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Diluted shares are restated to the current share basis (stock splits or reverse splits), chaining year-over-year changes reported in each 10-K.
Returns by year
| Year | IDXX | S&P 500 |
|---|---|---|
| 2019 | +40.4% | +31.5% |
| 2020 | +91.4% | +18.4% |
| 2021 | +31.7% | +28.7% |
| 2022 | −38.0% | −18.1% |
| 2023 | +36.1% | +26.3% |
| 2024 | −25.5% | +25.0% |
| 2025 | +63.6% | +17.9% |
| 2026 to date | +1.9% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Healthcare
- IBRX ImmunityBio Down 17.7%
- LEGN Legend Down 16%
- IRTC iRhythm Down 30.7%
- VCYT Veracyte Down 54.3%
- PACB PacBio Down 11.4%
Questions about IDEXX Laboratories
- How does IDEXX make money?
- Mostly from tests that vets buy again and again: supplies for the IDEXX analyzers in their clinics, quick in-clinic test kits and its outside reference labs. These recurring diagnostics were about 79% of its $4.30 billion of revenue in 2025; analyzers, practice software, water tests and livestock tests make up the rest. More in the Long View →
- What drives IDEXX's growth?
- More testing per visit rather than more visits: IDEXX places analyzers such as inVue Dx in clinics, adds new tests to them, wins customers and raises prices. By its own measure, organic revenue grew 10% a year from 2020 to 2025. More in the Long View →
- What could slow IDEXX's growth?
- Fewer vet visits: most of its revenue comes from tests run on patients, and U.S. same-store clinical visits have been falling, by about 2% in 2025. IDEXX also names competition from Mars and Zoetis and pricing pressure from corporate hospital groups and buying consortiums as risks. More in the Long View →
- How dependent is IDEXX on a few customers?
- Not on customers: no customer accounted for more than 10% of revenue in 2025. It does depend on one supplier, Ortho-Clinical Diagnostics, for the slides used in its Catalyst chemistry analyzers, under agreements set to run until December 2044. More in the Long View →
- Does IDEXX buy back its own shares?
- IDEXX spent about $3.7 billion buying back 7.6 million shares from 2021 to 2025, about four times the new shares it issued, so shares outstanding fell 6.7%. It pays no dividend. More in the Long View →